KOSDAQBiotech & Pharma085660

Chabiotech

₩7,540▲ 0.13%2026-11-18 close
Market Cap
₩701B
Turnover
₩1.8B
Volume
240K
Shares out.
93M
PER
—
PBR
2.1×
EPS
-₩49
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Holds Up but Losses Persist; Turnaround Is the Test

Chabiotech's revenue has declined for three straight quarters through the third quarter of 2026 and operating losses have run for five, so whether its CGT CDMO and digital healthcare investments convert into profit is the key test.

  1. 1

    Revenue in 2025 reached KRW 1.27 trillion, up 21.4% year on year, yet the company still posted an operating loss of KRW 48.8 billion that year. Top-line growth has not yet translated into operating profit.

  2. 2

    Revenue in the third quarter of 2026 was KRW 255.5 billion, down 19.8% from a year earlier, and the operating loss widened to KRW 24.2 billion. A sharp drop in other-income revenue and higher finance costs both weighed on results.

  3. 3

    Net income attributable to owners of the parent was KRW 15.6 billion in Q1 2026 and KRW 29.3 billion in Q2, but a net loss of KRW 29.8 billion in Q3 turned the figure negative again.

  4. 4

    Asset sales and a group restructuring improved non-operating items, and the nine-month net loss narrowed from a year earlier, according to press coverage of the November 13, 2026 disclosure.

  5. 5

    The debt-to-equity ratio rose from 146.5% in 2022 to 214.8% in 2025, with total liabilities of KRW 1.74 trillion at year-end 2025. Financial leverage has increased.

02

Business structure

Chabiotech's business spans four areas: global healthcare, domestic profit businesses, cell and gene therapy (CGT) development and contract manufacturing (CDMO), and AI-based digital healthcare.

Overseas medical services are the largest contributor, with the company operating medical institutions and providing fertility and reproductive medicine services in the United States, Singapore and Australia.

In the third quarter of 2026, hospital revenue was KRW 177.2 billion, the bulk of consolidated revenue of KRW 255.5 billion, and it fell 6.8% from a year earlier.

Product sales rose 10.5% to KRW 12.3 billion and service revenue rose 14.9% to KRW 31.4 billion, while goods sales fell 22% to KRW 26.1 billion and other-income revenue dropped 85.1% to KRW 8.5 billion.

On a standalone basis, BI, IT and cord blood businesses drove cumulative nine-month revenue of KRW 48.9 billion, up 8% year on year.

In CGT, the U.S. subsidiary Matica Biotechnology has expanded contracts with local biotech companies and is pursuing new clients through a K-FIH program that links U.S. manufacturing with Korean clinical capacity.

Key pipeline assets include CHAGE-201 for idiopathic pulmonary fibrosis, the NK cell therapy CBT101 for solid tumors, CBT210-POI for premature ovarian insufficiency, and PlaSTEM-AD for Alzheimer's disease.

In CDMO, the company is compared with large contract manufacturers such as Samsung Biologics, while its bispecific antibody efforts overlap with antibody-focused peers such as ABL Bio.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩318.7B-₩8.1B−2.5%
2025Q4₩346.5B-₩7.4B−2.1%
2026Q1₩329.7B-₩30.7B−9.3%
2026Q2₩316.4B-₩28.2B−8.9%
2026Q3₩255.5B-₩24.2B−9.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩844.6B-₩47.1B-₩47.5B−5.6%−16.3%146.5%
2023₩954B-₩9.6B-₩8.4B−1.0%−3.0%162.9%
2024₩1T-₩59.7B-₩8.1B−5.7%−2.8%205.3%
2025₩1.3T-₩48.8B-₩109.9B−3.8%−36.1%214.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 844.6 billion in 2022 to KRW 954 billion in 2023, KRW 1.05 trillion in 2024 and KRW 1.27 trillion in 2025. Revenue increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating losses ran from KRW 47.1 billion in 2022 to KRW 9.57 billion in 2023, KRW 59.7 billion in 2024 and KRW 48.8 billion in 2025, making four straight years of operating losses from 2022 through 2025.

The operating margin was -5.6% in 2022, -1.0% in 2023, -5.7% in 2024 and -3.8% in 2025, so margins did not improve meaningfully as revenue grew. Net loss attributable to owners widened to KRW 109.9 billion in 2025 from KRW 8.05 billion in 2024. Net loss including non-controlling interests was KRW 146.7 billion in 2025.

Operating cash flow was negative in 2022, 2024 and 2025 at -KRW 20.6 billion, -KRW 49.5 billion and -KRW 72.5 billion, with the exception of 2023 at KRW 11.5 billion.

Quarterly revenue peaked at KRW 346.5 billion in Q4 2025 and then fell to KRW 329.7 billion in Q1 2026, KRW 316.4 billion in Q2 and KRW 255.5 billion in Q3. The operating loss has been recorded for five straight quarters from Q3 2025 through Q3 2026.

For Q1 2026, the company attributed the KRW 30.7 billion operating loss to expansion of its digital healthcare business and CGT R&D spending. In Q3 2026, gross profit fell 17.7% year on year to KRW 76.3 billion, while finance costs rose to KRW 62.7 billion from KRW 8.4 billion a year earlier.

Net income attributable to owners was positive in Q1 and Q2 2026, and the company linked the first-half net income turnaround to portfolio restructuring and asset efficiency. Other income of KRW 50.8 billion in Q3 also shows how much non-operating items shape reported results.

05

Industry analysis

The cell and gene therapy market requires both clinical development capability and manufacturing capacity.

The company says it has built GMP manufacturing processes, a cell bank and quality control systems for its mesenchymal stem cell-based platform, and it also participates as a joint R&D institution in a Ministry of Science and ICT platform project for advanced biopharmaceutical quality evaluation.

Government support of KRW 3.15 billion over three and a half years is meaningful for platform development but does not cover the full cost of the pipeline.

In CDMO, large contract manufacturers such as Samsung Biologics with extensive production capacity set the reference point, and Chabiotech is trying to differentiate by combining cell therapy-focused manufacturing with U.S. production infrastructure.

In bispecific antibodies, the company is compared with antibody-focused peers such as ABL Bio and LigaChem Biosciences. Many of its pipeline assets are in early clinical or IND-preparation stages, so individual candidate progress is likely to matter more to the business than broader cycle trends.

Its cord blood business is an established domestic base that the company plans to extend into stem cell storage services.

06

Outlook

The near-term milestone the company has cited is an IND application in Korea for CHAGE-201. Under the K-HERO project, the company plans to further verify efficacy and mechanism of action, build a cell bank, GMP manufacturing and quality testing systems, and complete nonclinical safety studies needed for the IND.

It intends to widen indications first to fibrotic diseases and later extend to neurological and autoimmune diseases. The company also describes a plan to link its CHAMS cell platform with its CHAGE gene-enhancement technology into a broader CGT development platform.

Its U.S. subsidiary has signed contracts with local biotech companies and is pursuing new clients and larger orders. Bispecific antibody candidates, global licensing and joint development are also presented as commercialization routes.

Press reports put consolidated cash and cash equivalents at KRW 303.4 billion at the end of June 2026, up from KRW 237.6 billion at the end of 2025. The management team led by Cha Won-tae took office in March 2026, and R&D headcount was reported at 122.

Stem cell storage services are planned as a way to diversify revenue from the existing cord blood base. The next verifiable markers are the IND filing, how CDMO contracts are reflected in revenue, and the annual results in the 2026 annual report.

07

Valuation

PER
—
PBR
2.1×
ROE
-1.1%
EPS
-₩49
BPS
₩3,651
Dividend per share
₩0

A profit-based multiple cannot currently be calculated. Because the owner-attributable net loss over the most recent four quarters is negative, the price-to-earnings ratio is not computed. The price-to-book ratio places the stock at a premium to the book value of equity attributable to owners.

Within total equity of KRW 809.2 billion, owners' equity is KRW 304.6 billion, and the large non-controlling interest share means the two equity measures should be read separately. The dividend yield is below the sector average.

The first-half 2026 profit turnaround mixes asset sales and non-operating items, which limits how far it can be used to judge earnings power. Compared with its own historical price-to-book band, the current level sits toward the upper end.

Earnings-based comparison with peers will become more meaningful only if the operating loss narrows on a quarterly basis.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Owner-attributable profit turned positive in 2026

Net income attributable to owners of the parent turned positive at KRW 15.6 billion in Q1 2026 and rose 87.3% quarter on quarter to KRW 29.3 billion in Q2.

Net income including non-controlling interests also turned positive in the first half of 2026, which the company attributed to portfolio restructuring and asset efficiency. Q3 returned to a net loss of KRW 29.8 billion, so whether this profit stretch lasts remains to be confirmed.

Asset efficiency expands cash capacity

In March 2026 the company sold its 46.5% stake in Solidus Investment to JW Holdings and transferred Cha Vaccine Institute shares for about KRW 23.8 billion.

According to a press report, consolidated cash and cash equivalents stood at KRW 303.4 billion at the end of June 2026, up from KRW 237.6 billion at the end of 2025. A restructuring of its stake in a healthcare affiliate also brought in new financial investors. The larger cash position provides a base for continued pipeline spending.

CGT contract manufacturing and government-backed pipeline

The U.S. subsidiary has expanded contracts with local biotech companies and is pursuing new clients through a K-FIH program that combines U.S. manufacturing with Korean clinical capacity.

Selected for a follow-on K-HERO project, the company will receive KRW 3.15 billion over three and a half years to pursue a domestic IND for CHAGE-201. Work on bispecific antibody candidates runs alongside, adding room to expand the pipeline. The key question for this strength is how much CDMO contract activity turns into reported revenue.

09

Bear factors

Revenue down for three straight quarters

Quarterly revenue fell from KRW 329.7 billion in Q1 2026 to KRW 316.4 billion in Q2 and KRW 255.5 billion in Q3. Other-income revenue dropped 85.1% in the third quarter, and hospital revenue fell 6.8%. The slowdown in overseas medical services pulled down the top line.

With selling and administrative expenses holding steady, fixed cost pressure becomes more visible as revenue shrinks.

Persistent operating losses and finance cost burden

The operating loss narrowed from KRW 30.7 billion in Q1 2026 to KRW 28.2 billion in Q2 and KRW 24.2 billion in Q3, yet it has been recorded for five straight quarters. Finance costs in Q3 rose to KRW 62.7 billion from KRW 8.4 billion a year earlier.

Net income attributable to owners swung back to a net loss of KRW 29.8 billion in Q3. Separating operating improvement from non-operating gains is necessary to judge the earlier profit stretch.

High leverage and negative operating cash flow

The debt-to-equity ratio rose from 146.5% in 2022 to 214.8% in 2025. Total liabilities were KRW 1.74 trillion at year-end 2025 against total equity of KRW 809.2 billion, of which owners' equity was KRW 304.6 billion.

Operating cash flow was negative two years in a row, at -KRW 49.5 billion in 2024 and -KRW 72.5 billion in 2025. Funding and repayment needs could constrain the pace of expansion.

10

Risk factors

Pipeline clinical and development risk

An IND filing for CHAGE-201 requires completing nonclinical safety studies and building CMC systems. Many key candidates remain in early clinical or IND-preparation stages, so development timelines could slip or licensing could be delayed.

The K-HERO grant over three and a half years does not cover the full development cost. Investment accumulates over a long period before clinical results emerge.

Earnings structure and reliance on one-off gains

The quarterly profit was attributed to stake sales and improved non-operating items. Once asset sales are exhausted, the same effect is unlikely to repeat. Other income rose to KRW 50.8 billion in Q3, yet owner-attributable results still turned to a loss, which signals that the operating base remains thin. Cash from asset sales is finite, and that could narrow financial flexibility.

Overseas operations and regulatory environment

Overseas revenue is significant across the United States, Australia, Singapore and Japan, so the business is exposed to local medical regulation and currency movements. Demand for fertility and reproductive medicine services can shift with local regulation and insurance conditions.

Commercialization timing for cell therapies depends on changes to Korea's advanced regenerative medicine framework and approval standards. Because these rules can change substantially, timelines are hard to predict.

11

What to watch next

  1. End of March 2027 (statutory deadline for the annual report)

    The 2026 annual report will finalize full-year 2026 revenue, operating loss, owner-attributable net income and Q4 results. The checkpoints are whether the revenue decline carried into the full year and how the debt-to-equity ratio and operating cash flow moved.

  2. Around mid-May 2027 (Q1 2026 results were disclosed on May 15)

    Q1 2027 results will show whether the revenue decline continues and whether the operating loss narrows further. Whether owner-attributable net income stays positive is also a key marker.

  3. Within the three-and-a-half-year K-HERO period selected in August 2026 (IND filing timing not disclosed)

    Watch for the domestic IND filing for CHAGE-201, the nonclinical safety results, and completion of the cell bank and GMP systems. Visible progress into the clinic would give a firmer basis for assessing the pipeline.

  4. Ad hoc disclosures (timing not set)

    Check the size of U.S. subsidiary CDMO contracts and how they are reflected in revenue. If contract values are disclosed, the revenue contribution of the contract manufacturing business can be gauged.

12

Overall view

Chabiotech's revenue grew for three consecutive years through 2025, yet operating losses persisted for four straight years over the same period. Revenue has fallen for three straight quarters in 2026, and the operating loss widened to KRW 24.2 billion in the third quarter.

Owner-attributable net income was positive in Q1 and Q2 2026 but turned to a net loss of KRW 29.8 billion in Q3. Asset sales and the group restructuring increased cash and improved non-operating items, but these should be separated from improvements in operating profitability.

On the balance sheet, the debt-to-equity ratio rose to 214.8% at the end of 2025, and operating cash flow was negative at -KRW 72.5 billion in 2025. On the business side, CGT CDMO, digital healthcare and pipeline progress toward the clinic are the growth pillars.

Strengths include asset efficiency, government-backed projects and expanding overseas CDMO contracts, while weaknesses include persistent operating losses and financial burden. The next checkpoints are the operating margin in the 2026 annual report and the revenue trend in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. getnews.co.kr
  2. weekly.hankooki.com
  3. daily.hankooki.com
  4. dealsite.co.kr
  5. pointdaily.co.kr
  6. news.chabio.com
  7. thebionews.net
  8. newspim.com
  9. dealsite.co.kr
  10. medipana.com
  11. businesskorea.co.kr
  12. fnnews.com
  13. m.news.nate.com
  14. ajunews.com
  15. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis